^
Association details:
| Biomarker: | SEMA7A expression |
|---|---|
| Cancer: | Breast Cancer |
| Drug: | Venclexta (venetoclax) (Bcl2 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Abstract 60: Semaphorin 7a promotes cell survival and resistance to endocrine therapy in ER+ breast cancer
Published date:
05/15/2020
Excerpt:
...patients with high Semaphorin 7a expression be considered as candidates for the addition of Venetoclax, an FDA approved Bcl2 targeted therapy, to their current therapeutic regimen...
DOI:
10.1158/1538-7445.AM2020-60